Dr. Prabir Chakraborty is a Senior Project Manager working in the Project Management department directing Early Oncology Drug Development programs at Bristol Myers Squibb (BMS). Before joining BMS, Dr. Chakraborty worked in a senior management role for Research Strategic Operations at Gilead Sciences (CA, USA) where he planned and executed various CAR-T pipeline development in both solid and heme tumors. Dr. Chakraborty has been a seasoned research and corporate strategists in the biotechnology industry. He has patents pertaining to immunooncology assets that have paved way to clinical trials.
Dr. Chakraborty came to Gilead Sciences from Arch Oncology, where he led immuno-oncology programs targeting CD47 in both solid and hematological cancers. He was involved in managing IND enabling studies, translational research and new pipeline development. Prior to that, Dr. Chakraborty was a Research Assistant Professor at Stephenson Cancer Center in Oklahoma focusing on ovarian and pancreatic cancer research. Dr. Chakraborty received his PhD from Jadavpur University, targeting signaling pathways as a combinatorial therapy for chronic myelogenous leukemia and conducted his post-doctoral research at the University of Florida on novel GPCR targets in prostate cancer.